METTL3 and acute myeloid leukemia: STM2457, a bioavailable and highly selective METTL3 inhibitor, can significantly increase CD40+ expression, reduce the presence of AML cells from peripheral blood, act on crucial stem cell lines, and promote phenotypic reversal to prevent the development of AML.